Nektar Therapeutics is launching the first two global registrational trials (ZENITH AD-1 and ZENITH AD-2) in the Phase 3 ZENITH AD program for rezpegaldesleukin.
The ZENITH AD program is evaluating rezpegaldesleukin in patients aged 12 years and up with moderate-to-severe atopic dermatitis (AD). The program includes three global, randomized, double-blind, placebo-controlled trials: ZENITH AD-1 and ZENITH AD-2 will enroll biologic and systemic Janus Kinase (JAK) inhibitor treatment-naive patients and ZENITH AD-3 will enroll patients with prior systemic biologic and/or JAK inhibitor treatment experience.
Initial Phase 3 top-line data are expected in mid-2028 with a Biologics License Application (BLA) submission targeted for 2029.
Rezpegaldesleukin is a first-in-class regulatory T-cell (T-reg) biologic designed to address imbalances in the immune system that underlie many autoimmune disorders and chronic inflammatory conditions. It targets the interleukin (IL)-2 receptor complex to preferentially stimulate the proliferation of T-regs to restore immune balance.
“Initiating our Phase 3 program in atopic dermatitis takes us one step closer to bringing this important regulatory T-cell-targeted mechanism to patients,” says Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics, in a news release. “We designed a robust registrational program in atopic dermatitis from our compelling Phase 2b data, and we expect initial data from ZENITH AD in mid-2028.”
In early 2027, the Company plans to initiate a single registrational Phase 3 trial in alopecia areata, based upon data from its randomized, placebo-controlled Phase 2b study.
The ZENITH AD program and the Phase 3 registrational trial in alopecia areata were designed following completion of End-of-Phase 2 meetings with the Food and Drug Administration (FDA) and scientific advice from the European Medicines Agency (EMA) and are intended to support both US and European registration in both indications.